Dyne Therapeutics (NASDAQ:DYN) Insider Sells $24,355.20 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 1,290 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $24,355.20. Following the sale, the insider directly owned 162,564 shares in the company, valued at $3,069,208.32. This trade represents a 0.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Friday, September 4th, Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock. The shares were sold at an average price of $24.35, for a total value of $91,190.75.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN opened at $18.42 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The business has a 50-day moving average of $24.68 and a 200-day moving average of $20.54. The stock has a market capitalization of $3.44 billion, a price-to-earnings ratio of -5.53 and a beta of 1.08. Dyne Therapeutics, Inc. has a fifty-two week low of $11.92 and a fifty-two week high of $27.31.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.33). As a group, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics during the 1st quarter worth about $26,000. Strs Ohio bought a new position in Dyne Therapeutics in the 4th quarter valued at about $51,000. Allworth Financial LP acquired a new stake in Dyne Therapeutics during the second quarter worth approximately $62,000. Aster Capital Management DIFC Ltd acquired a new stake in Dyne Therapeutics during the fourth quarter worth approximately $84,000. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on DYN shares. JPMorgan Chase & Co. cut shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and decreased their target price for the company from $17.00 to $10.00 in a research note on Wednesday. Royal Bank Of Canada cut their price target on shares of Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, August 17th. Robert W. Baird lowered their price objective on shares of Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, Wall Street Zen downgraded shares of Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.17.

Key Stories Impacting Dyne Therapeutics

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Morgan Stanley reaffirmed its Buy rating on Dyne, signaling continued confidence in the company’s pipeline and long-term outlook. Morgan Stanley reaffirmed Buy rating
• Positive Sentiment: RBC maintained an Outperform rating, saying Dyne’s DM1 approach remains differentiated, although it reduced its price target from $35 to $30. Investors are also awaiting additional six- and 12-month data for DYNE-101 and topline results from the fully enrolled ACHIEVE expansion cohort, expected in the first quarter of 2027. RBC assessment of Dyne’s DM1 approach
• Neutral Sentiment: Unusually heavy call-option activity was reported, with roughly 20,532 calls traded versus average daily volume of about 464. The activity may indicate speculative expectations for a rebound or clinical-data catalyst, but it does not establish improving fundamentals. Unusually large options trading in DYN
• Neutral Sentiment: Reported short interest was zero shares, implying no meaningful short-selling position or days-to-cover exposure based on the figures provided. This is unlikely to be a major near-term trading catalyst.
• Negative Sentiment: JPMorgan downgraded DYN from Neutral to Underweight and cut its price target from $17 to $10. The move followed a rival DM1 therapy’s Phase 3 failure, which raised concerns about clinical and commercial risks across the disease class. JPMorgan downgrade following Novartis setback
• Negative Sentiment: An insider sold 900 shares for approximately $21,915, reportedly to cover tax withholding tied to vested equity awards. The sale was small relative to the insider’s remaining holdings, limiting its fundamental significance, but it may add modestly to cautious sentiment. Dyne insider stock sale

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.